 Moneycontrol.com | Another negative Indian patent ruling, this time for Pfizer's Sutent The Pharma Letter ... for liver and kidney cancer, arguing that the company's patent does not involve any inventive step. The post-grant opposition was filed by Mumbai-based Cipla (BSE: 50087) and Natco Pharma (524816: BY. Pfizer India will appeal before Intellectual ... Pharma cos strong performance may continue in Q2 |
